Appeal finds NICE decision on £90k breast cancer drug 'unfair'

By Sarah Calkin2014-12-16T09:52:00

Source: Science Photo Library

The impact of the government’s drug pricing deal on patient access to new medicines has been thrown into confusion after a pharmaceutical company’s appeal against the decision to ban routine NHS funding of one of its drugs was upheld.

You need to be signed in to read more

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

All of HSJ.co.uk and our HSJ mobile app
News and insight on all areas of public funded healthcare
Expert commentary, insight and analysis from industry leaders
9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

to HSJ

Sign into your account here